The Latest Ischemic Stroke Industry Statistics Explained
Approximately 87% of all strokes are ischemic strokes.
This statistic indicates that a large majority, around 87%, of all strokes are categorized as ischemic strokes. Ischemic strokes occur when a blood clot blocks or narrows a blood vessel in the brain, leading to a lack of blood flow and oxygen. By contrast, hemorrhagic strokes occur when a blood vessel bursts in the brain. Understanding that most strokes are ischemic can be crucial for healthcare professionals, policymakers, and the public to focus resources on prevention and treatment strategies specific to this type of stroke, such as clot-busting medications or interventions to manage risk factors like high blood pressure and cholesterol levels.
The global market value of ischemic stroke is predicted to reach USD 32.4 billion by 2025.
The statistic ‘The global market value of ischemic stroke is predicted to reach USD 32.4 billion by 2025’ refers to the estimated total worth of the market for products and services related to ischemic strokes at a global level. This prediction indicates a significant economic value associated with the medical treatments, pharmaceuticals, devices, and other healthcare services geared towards preventing, diagnosing, and managing ischemic stroke cases. The projected increase in market value signals a growing demand for these products and services driven by factors such as an ageing population, lifestyle changes, and advancements in medical technology. This statistic serves as an important indicator for stakeholders in the healthcare industry, highlighting the market potential and opportunities for innovation and investment in combating and addressing ischemic stroke.
The North American region accounted for the largest market share of 35.5% in 2018 in the ischemic stroke industry.
The statistic “The North American region accounted for the largest market share of 35.5% in 2018 in the ischemic stroke industry” means that among all global regions, North America had the highest proportion of market sales for products related to ischemic stroke in the specific year of 2018. This indicates that North America was the most significant market for ischemic stroke-related products in terms of revenue or sales volume compared to other regions such as Europe, Asia, or others. Understanding this statistic is crucial for companies and stakeholders operating in the ischemic stroke industry to strategically target and allocate resources effectively in order to capitalize on the opportunities present in the North American market.
Genentech, Inc., Bayer AG, and Bristol-Myers Squibb Company are some of the key players in the ischemic stroke industry.
The statistic highlights key players in the ischemic stroke industry, specifically naming Genentech, Inc., Bayer AG, and Bristol-Myers Squibb Company as significant contributors. These companies are likely prominent in terms of research, development, and commercialization of products and therapies related to ischemic stroke, which is a type of stroke caused by a blockage in a blood vessel that supplies blood to the brain. By identifying these key players, the statistic suggests that they have a strong presence and influence within the industry, potentially leading innovations in treatment options for patients suffering from ischemic strokes.
Approximately 795,000 individuals suffer from a new or recurrent stroke annually in the U.S.
The statistic states that around 795,000 individuals in the United States experience either a new or recurrent stroke each year. A stroke occurs when there is a disruption in the blood supply to the brain, leading to damage of brain cells and potential long-term effects on an individual’s physical and cognitive functions. Strokes are a serious health concern as they can have debilitating consequences and can even be life-threatening. Understanding the prevalence of strokes in the population is crucial for healthcare professionals, policymakers, and researchers to develop effective prevention strategies, provide appropriate treatment, and improve overall public health outcomes in the United States.
In 2017, 2.8% of Americans over the age of 18 had a stroke.
The statistic “In 2017, 2.8% of Americans over the age of 18 had a stroke” indicates the prevalence of strokes within the adult population in the United States during that year. This percentage suggests that strokes were a health concern affecting a notable proportion of the population above the age of 18 in 2017. Strokes are serious medical emergencies that occur when blood flow to the brain is disrupted, leading to potential long-term disabilities or even death. The statistic underscores the importance of public health initiatives and preventative measures aimed at reducing the incidence of strokes and promoting overall cardiovascular health among American adults.
The Ischemic stroke market in Asia-Pacific is expected to grow at a significant CAGR of 7.6% from 2020-2027.
The statistic indicates that the Ischemic stroke market in the Asia-Pacific region is projected to experience robust growth with a Compound Annual Growth Rate (CAGR) of 7.6% from 2020 to 2027. This implies that the market for products and services related to Ischemic stroke, such as medications, medical devices, and treatment options, is expected to expand steadily over the forecast period. The increasing prevalence of Ischemic strokes in the region, coupled with advancements in healthcare technologies and rising awareness about stroke prevention and management, are likely driving this growth. Investors, healthcare providers, and stakeholders in the industry may benefit from these insights to make informed decisions and capitalize on the expanding Ischemic stroke market in the Asia-Pacific region.
The fastest growth in the ischemic stroke market is anticipated in the Middle East and Africa region, at a CAGR of 11.8% from 2020-2027.
This statistic indicates that the ischemic stroke market in the Middle East and Africa region is projected to experience rapid growth over the period from 2020 to 2027, with a compound annual growth rate (CAGR) of 11.8%. This implies that the market for ischemic stroke treatments and related products is expected to expand at a relatively high pace in this region compared to other regions. Factors contributing to this growth could include an increasing prevalence of ischemic stroke cases, improvements in healthcare infrastructure, rising awareness about the condition, and advancements in medical technologies. Companies operating in this market may find opportunities for expansion and innovation in order to meet the growing demand for ischemic stroke treatments in the Middle East and Africa region.
Computed Tomography (CT) technology dominated the global acute ischemic stroke diagnosis market in 2020.
In 2020, Computed Tomography (CT) technology emerged as the leading diagnostic tool for acute ischemic stroke on a global scale. This dominance likely stems from the widespread availability, quick imaging capabilities, and accurate detection of ischemic stroke using CT scans. The efficiency of CT technology in identifying key diagnostic markers such as blocked blood vessels or brain damage associated with ischemic stroke likely contributed to its prominence in the market. Furthermore, the ability of CT scans to rapidly provide critical information necessary for timely treatment decisions in cases of acute ischemic stroke likely solidified its position as the top diagnostic modality in this particular healthcare context.
The ischemic stroke market is expected to record a CAGR of 6.8% from 2021 to 2026.
This statistic means that the ischemic stroke market is projected to experience a Compound Annual Growth Rate (CAGR) of 6.8% from 2021 to 2026. CAGR is a measure used to understand the annual growth rate of an investment over a specified period of time. In this context, it indicates the annual rate at which the market for ischemic stroke treatments is expected to expand over the 5-year period from 2021 to 2026. A CAGR of 6.8% suggests a healthy and steady growth trajectory for the market, indicating increasing demand for ischemic stroke-related products and services, as well as potential advancements in treatment options and healthcare technologies during this period.
China holds a significant share in the Asia-Pacific ischemic stroke industry.
The statistic ‘China holds a significant share in the Asia-Pacific ischemic stroke industry’ signifies that China plays a prominent role in the market for ischemic stroke treatment and management within the Asia-Pacific region. This may mean that China accounts for a considerable portion of ischemic stroke cases, healthcare resources, research and development activities, or market revenue within the region. The statement suggests that China’s impact on the ischemic stroke industry is substantial and highlights the country’s importance in addressing the healthcare needs related to ischemic stroke in the Asia-Pacific region.
In the United States, the total cost of stroke is estimated to be $34 billion per year.
The statistic states that in the United States, the annual cost of stroke is estimated to be $34 billion. This figure encompasses the economic burden associated with stroke, including direct medical costs such as hospitalization, medication, and rehabilitation services, as well as indirect costs like loss of productivity and income due to disability or premature death. The high economic cost of stroke underscores the significant impact that this condition has on both individuals and society as a whole. By quantifying the financial implications of stroke, policymakers, healthcare providers, and researchers can better understand the scope of the problem and allocate resources effectively to prevent, treat, and manage this debilitating health issue.
The use of thrombolytic drugs for the treatment of ischemic stroke is expected to increase in the coming years.
The statistic indicates that there is a growing trend towards the utilization of thrombolytic drugs as a treatment option for ischemic stroke. This shift suggests that healthcare professionals and researchers anticipate a rise in the administration and prescription of these medications in the foreseeable future. This anticipated increase could be driven by advancements in medical technology, a better understanding of the benefits of thrombolytic therapy, and an overall improvement in healthcare practices aimed at combating ischemic strokes effectively. It reflects a positive development in the medical field as more options for treating this serious condition become more widely available and are expected to be more frequently utilized to improve patient outcomes in the years ahead.
Roughly 58% of global stroke deaths in 2016 occurred in lower-middle-income countries.
The statistic suggests that a substantial majority, approximately 58%, of all stroke-related deaths worldwide in 2016 were concentrated in lower-middle-income countries. This highlights a concerning disparity in stroke mortality rates between different income levels, indicating that individuals living in these lower-middle-income countries are disproportionately affected by strokes compared to those in higher-income regions. The statistic underscores the need for targeted public health interventions and resources to address the unique challenges faced by these populations, such as access to healthcare services, awareness campaigns, and prevention strategies. Addressing these disparities could help reduce the burden of stroke-related deaths in lower-middle-income countries and improve overall global health outcomes.
The average age at the first stroke is 70 years old for men and 76 years old women.
The statistic suggests that, on average, men experience their first stroke at a younger age of 70 years old compared to women, who tend to have their first stroke at an average age of 76 years old. This indicates a significant difference in the age at which men and women are likely to be affected by a stroke for the first time. Such information is valuable for healthcare professionals and policymakers to understand the risk factors and potential preventive measures that may need to be tailored differently for men and women to reduce the incidence of strokes in each group.
By 2030, up to 3.88 million people can be expected to suffer stroke-related costs in the U.S.
This statistic indicates that by the year 2030, it is projected that as many as 3.88 million people in the United States will incur costs related to strokes. This includes expenses such as medical treatment, rehabilitation, long-term care, and lost productivity. Strokes can have a significant impact on individuals’ health and quality of life, as well as on the healthcare system and the economy as a whole. Understanding and preparing for the potential financial burden of stroke-related costs is essential for policymakers, healthcare providers, and individuals to effectively address this public health challenge and provide adequate support and resources for those affected by strokes.
For every minute delay in treating a stroke, the average patient loses 1.9 million neurons.
The statistic that for every minute delay in treating a stroke, the average patient loses 1.9 million neurons highlights the critical importance of swift and timely medical intervention in cases of stroke. Neurons are the building blocks of the brain and losing a large number of them can significantly impact a patient’s cognitive and physical functions. Therefore, delays in treatment can lead to substantial neurological damage, potentially resulting in long-term disabilities or even death. This statistic underscores the urgent need for rapid response and efficient medical care to minimize neuronal loss and improve outcomes for stroke patients.
References
0. – https://www.www.who.int
1. – https://www.www.alliedmarketresearch.com
2. – https://www.www.cdc.gov
3. – https://www.www.stroke.org
4. – https://www.www.gminsights.com
5. – https://www.www.grandviewresearch.com
6. – https://www.www.mordorintelligence.com
7. – https://www.www.ncbi.nlm.nih.gov
